UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2018

Commission File Number: 001-32001

___________________

Aptose Biosciences Inc.
(Translation of registrant's name into English)

251 Consumers Road, Suite 1105
Toronto, Ontario  M2J 4R3
Canada
 ( Address of principal executive offices )
___________________


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F £   Form 40-F R

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)  £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)  £
 

 
 
 

 
INCORPORATION BY REFERENCE

This Report on Form 6-K is hereby incorporated by reference as an Exhibit to the Registration Statement on Form F-10 of Aptose Biosciences Inc. (File No. 333-222909).


DOCUMENTS FILED AS PART OF THIS FORM 6-K

Exhibit
Description
   
99.1
Material Change Report, dated June 8, 2018


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Aptose Biosciences Inc.


Date: June 8, 2018
By: /s/ Gregory Chow                                        
Name: Gregory Chow
Title: Senior Vice President and Chief Financial Officer
 
 
2

Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aptose Biosciences Charts.
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aptose Biosciences Charts.